tegafur/uracil / Generic mfg. - LARVOL DELTA

Efficacy of UFT combined with radiotherapy in advanced pancreatic cancer: a systematic review and meta-analysis. (PubMed, Front Oncol) - "Tegafur-uracil (UFT) combined with radiotherapy is a treatment option for advanced pancreatic cancer...However, further research is needed to confirm these findings in large-scale randomized controlled trials. https://www.crd.york.ac.uk/PROSPERO/view/CRD420261377332, identifier, CRD420261377332."

Journal • Retrospective data • Review • Oncology • Pancreatic Cancer • Solid Tumor

Tegafur-uracil maintenance chemotherapy post-chemoradiotherapy for cervical cancer: Randomized trial. (PubMed, Eur J Cancer) - "These findings suggest the need to reconsider maintenance therapy strategies after CCRT for potentially shifting away from cytotoxic chemotherapy towards alternative methods to enhance survival outcomes in patients with LACC."

Journal • Cervical Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma

Tegafur-Uracil (UFUR) as Maintenance Therapy in Resectable and Unresectable Head and Neck Squamous Cell Carcinoma: A Narrative Review. (PubMed, Oral Dis) - "Metronomic tegafur-uracil (UFUR), an oral fluoropyrimidine comprising tegafur and uracil, has emerged as a potential maintenance strategy because of its cytotoxic, immunomodulatory, and anti-angiogenic mechanisms mediated by 5-fluorouracil (5-FU) and gamma-hydroxybutyric acid (GHB). Published cohorts suggest potential benefits in selected high-risk patients and a generally manageable toxicity profile, but their findings remain susceptible to selection bias, residual confounding, and immortal-time bias. Prospective randomized trials are needed to confirm clinical benefit and define optimal treatment duration, patient selection, and potential integration with contemporary immunotherapy."

Journal • Review • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Inflammatory, Immune-Metabolic, and Vascular Biomarker Trajectories Across Treatment Modalities and Associations with Treatment-Related Complications in Oral Squamous Cell Carcinoma: A Prospective Study in Taiwan. (PubMed, Cancer Manag Res) - "This prospective cohort study included patients with OSCC receiving surgery alone, surgery followed by concurrent chemoradiotherapy (CCRT), or CCRT followed by tegafur-uracil (UFUR) maintenance...Blood-based and vascular biomarkers showed treatment-specific trajectories and were associated with clinically relevant complications. These exploratory findings may support risk-adapted toxicity monitoring in OSCC, although the proposed cutoffs require external validation."

Biomarker • Journal • Febrile Neutropenia • Hematological Disorders • Infectious Disease • Mucositis • Neutropenia • Oncology • Oral Cancer • Squamous Cell Carcinoma

Optimizing Outcomes in Elderly HNSCC: Efficacy of UFT Metronomic Therapy. (PubMed, Cancer Med) - "Metronomic UFT was associated with improved PFS and OS in elderly patients with advanced HNSCC and was well tolerated, with all adverse events limited to grade 1-2. Landmark analysis confirmed that the observed benefit was not attributable to immortal time bias. These exploratory findings warrant validation in prospective studies."

Journal • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Oral fluoropyrimidines as alternatives to intravenous 5-fluorouracil in combination with immune checkpoint inhibitors for recurrent metastatic head neck squamous cell carcinoma. (ASCO 2026) - "Although pembrolizumab combined with chemotherapy—including continuous intravenous 5-fluorouracil (5-FU)—achieves higher response rates than pembrolizumab alone, prolonged hospitalization and adverse events make this regimen challenging to implement in real-world practice. Oral tegafur-uracil demonstrated non-inferior outcomes compared to continuous intravenous 5-FU when combined with ICIs for R/M HNSCC. Prospective randomized controlled trials are warranted to confirm these findings. Hazard ratio between patients with or without oral tegafur-uracil for survival outcomes."

Checkpoint inhibition • Combination therapy • Metastases • Head and Neck Cancer • Oncology • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Pathologic response and surgical conversion after preoperative docetaxel, cisplatin, and oral 5-FU with or without PD-1 inhibitors in resectable HNSCC: A retrospective cohort study. (ASCO 2026) - "Funded by No funding sources reported Background: Induction chemotherapy with docetaxel, cisplatin, and fluorouracil (TPF) has been widely used in patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC), but its clinical utility is often limited by substantial toxicity. A modified regimen consisting of docetaxel, cisplatin, and oral tegafur–uracil (DCU) has been adopted as a more tolerable alternative... In this real-world cohort of patients with resectable HNSCC, induction DCU demonstrated acceptable efficacy and tolerability. The addition of pembrolizumab was feasible and associated with higher pCR rates and increased conversion to surgery. These findings warrant further investigation of pembrolizumab-based induction strategies with longer follow-up and larger prospective studies."

Retrospective data • Head and Neck Cancer • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Value of Carcinoembryonic Antigen Levels After Chemoradiotherapy for Advanced Low Rectal Cancer. (PubMed, Cancer Diagn Progn) - "CRT consisted of 45 Gy in 25 fractions with concurrent tegafur/uracil, followed by total mesorectal excision 8-10 weeks after CRT completion...Patients with lower post-CRT CEA showed significantly better DFS and OS. Post-CRT CEA is a valuable prognostic biomarker for recurrence and survival in advanced low rectal cancer, and patients with elevated post-CRT CEA may benefit from additional consolidation chemotherapy."

Journal • Colorectal Cancer • Embryonal Tumor • Oncology • Rectal Cancer • Solid Tumor • CEACAM5

Marked Response to Palliative Chemoradiotherapy for Esophageal Metastasis From Breast Cancer: A Case Report (GBCC 2026) - "Postoperatively, she received weekly paclitaxel (12 cycles), followed by letrozole and postmastectomy radiation therapy (60 Gy in 30 fractions). Oral tegafur/uracil was continued for approximately 3 years after completion of postmastectomy radiation therapy... Palliative concurrent chemoradiotherapy with S-1 achieved rapid symptomatic recovery and endoscopic improvement in esophageal metastasis from breast cancer. These findings suggest that palliative Poster Presentation concurrent chemoradiotherapy may be considered for symptomatic esophageal metastasis causing obstruction."

Case report • Clinical • Breast Cancer • Gastrointestinal Disorder • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ER • HER-2 • PGR

Long-term outcomes and prognostic factors of preoperative chemoradiotherapy with oral dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines in patients with locally advanced rectal cancer. (PubMed, J Med Invest) - "Evaluation of lateral lymph node before CRT is useful in predicting prognosis in patients with locally advanced lower rectal cancer treated with preoperative chemoradiotherapy with oral DPD-inhibiting fluoropyrimidines, and surgical planning to ensure a 1-mm circumferential resection margin is important for improving prognosis. J. Med. Invest. 73 : 62-67, February, 2026."

Biomarker • Journal • Retrospective data • Colorectal Cancer • Oncology • Rectal Cancer • Solid Tumor

Anti-cancer drug usage analysis among Korean patients with colorectal cancer (AACR 2026) - "Among monotherapies, 5-fluorouracil (5-FU) was most frequently used (45.96%)...Capecitabine was the most common regimen for monotherapy (21%)...In contrast, use of 5-FU significantly declined (p < 0.001), while use of oxaliplatin and bevacizumab markedly increased (both p < 0.001). Meanwhile, tegafur/uracil and megestrol usage decreased significantly (both p < 0.001)...Further analyses should link treatment patterns to clinical outcomes, including evaluations of overall survival (OS) and disease-free survival (DFS), clarification of treatment lines, and resolution of overlapping-prescription or regimen-coding issues. This study was approved by the Institutional Review Board of the NCC (NCC2025-0115)."

Clinical • Colorectal Cancer • Oncology • Solid Tumor

Tegafur/Uracil-Induced Sinusoidal Obstruction Syndrome as a Suspected Cause of Liver Cirrhosis during Adjuvant Chemotherapy for Lung Adenocarcinoma: A Case Report. (PubMed, Case Rep Oncol) - "UFT was discontinued, and supportive management was initiated, including albumin, diuretics, and ursodeoxycholic acid. This case represents the first reported instance in which UFT-induced hepatic injury was clinically, biochemically, and radiologically demonstrated to be consistent with SOS. It highlights a rare but serious hepatic complication of UFT and underscores that careful monitoring of fibrosis markers and radiologic findings - not only liver enzymes - is essential for early detection of drug-induced SOS during prolonged adjuvant chemotherapy."

Journal • Autoimmune Hepatitis • Fibrosis • Gastroenterology • Hematological Disorders • Hepatology • Immunology • Infectious Disease • Liver Cirrhosis • Liver Failure • Lung Adenocarcinoma • Lung Cancer • Metabolic Disorders • Non Small Cell Lung Cancer • Oncology • Solid Tumor

A Case of Tegafur-Uracil-Induced Interstitial Lung Disease Presenting as Hypersensitivity Pneumonitis. (PubMed, Cureus) - "After receiving tegafur-uracil (UFT) plus leucovorin in combination with bevacizumab for rectal cancer, he developed exertional dyspnea. DI-ILD associated with UFT is rare, and to the best of our knowledge, no previous reports have described an HP pattern on imaging. We therefore report this case with a review of the relevant literature."

Journal • Colorectal Cancer • Immunology • Infectious Disease • Inflammation • Interstitial Lung Disease • Lung Cancer • Oncology • Pneumonia • Pulmonary Disease • Rectal Cancer • Respiratory Diseases • Solid Tumor • CD4 • CD8

Hemophagocytic syndrome caused by Epstein-Barr virus and cytomegalovirus infection during neoadjuvant chemoradiotherapy for rectal cancer: a case report. (PubMed, Front Med (Lausanne)) - "Treatment for DLBCL was initiated first, and six courses of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy were administered, which led to a clinical complete response of the lymphoma lesions. Following the completion of DLBCL treatment, preoperative chemoradiotherapy with tegafur-uracil/leucovorin (UFT/UZEL) was initiated for rectal cancer...Epstein-Barr virus (EBV) and cytomegalovirus (CMV) infections were identified, and treatment to combat the infections was initiated; however, the patient passed away on Day 37. It is important to consider the possibility of HPS, and diagnosis and treatment initiation should occur in a timely manner when fever of an unknown origin and decreased blood cell counts are observed during malignant disease treatment."

Journal • Acute Respiratory Distress Syndrome • B Cell Lymphoma • Colorectal Cancer • Cytomegalovirus Infection • Diffuse Large B Cell Lymphoma • Epstein-Barr Virus Infections • Hematological Disorders • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Infectious Disease • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Pulmonary Disease • Rectal Cancer • Respiratory Diseases • Solid Tumor • Thrombocytopenia

Preoperative Chemoradiotherapy with Tegafur-Uracil, Capecitabine, or 5-Fluorouracil/Leucovorin for Rectal Cancer in an Asian Cohort: A Real-World Comparison from the Pre-TNT Era. (PubMed, Curr Oncol) - "UFT-based long-course CCRT appears feasible and generally tolerable in routine Asian practice, with no clear signal of substantially worse pCR or survival outcomes in this retrospective cohort. These real-world data can inform individualized regimen selection."

Journal • Real-world evidence • Colorectal Cancer • Hematological Disorders • Neutropenia • Oncology • Rectal Cancer • Solid Tumor

Gastric mucinous adenocarcinoma presenting with chronic cough, bronchovascular bundle thickening, and multiple pulmonary nodules: a case report. (PubMed, Front Oncol) - "One month post-surgery, the patient commenced regular chemotherapy with the SOX regimen (Oxaliplatin 170mg d1+Tegafur-uracil 50mg,bid,d1-d14,q21d).The patient received 6 cycles of chemotherapy and experienced no recurrence through follow-up via gastroscopy. This study reports a case of gastric mucinous adenocarcinoma with pulmonary lymphangitic carcinomatosis presenting as chronic cough. Our case report highlights the importance of emphasizing chronic cough, encouraging a broader diagnostic approach, and actively seeking and confirming the existence of potential extrapulmonary diseases to prevent missed diagnoses and misdiagnoses."

Journal • Chronic Cough • Cough • Gastric Cancer • Oncology • Pulmonary Disease • Respiratory Diseases • Solid Tumor

Pathological Response of Locally Recurrent Rectal Cancer to Neoadjuvant Chemoradiotherapy. (PubMed, J Anus Rectum Colon) - "A few patients showed score 1, including those treated with oxaliplatin or irinotecan in addition to tegafur and uracil/leucovorin. Direct assessment of apoptosis demonstrated that LRRC is resistant to CRT-induced apoptosis. This resistance likely contributes to high local and distant recurrence after surgery, underscoring the need to develop more effective perioperative strategies for LRRC."

Journal • Colorectal Cancer • Oncology • Rectal Cancer • Solid Tumor

Adjuvant metronomic tegafur-uracil is associated with poorer outcomes and unfavorable histopathologic progression in oral squamous cell carcinomas. (PubMed, J Dent Sci) - "Adjuvant metronomic UFUR provided no survival advantage and was associated with unfavorable histopathologic evolution in OSCCs. These findings warrant re-evaluation of UFUR as routine adjuvant therapy and support risk-adapted, molecularly guided postoperative strategies in oral cancer management."

Journal • Head and Neck Cancer • Oncology • Oral Cancer • Solid Tumor • Spindle Cell Sarcoma • Squamous Cell Carcinoma

Adjuvant Tegafur-Uracil Improves Survival in Low-Risk, Mismatch Repair Proficient Stage IIA Colon Cancer: A Propensity Score-Matched Analysis. (PubMed, Life (Basel)) - "UFT reduced the risk of recurrence or death by 57% (DFS HR = 0.43, 95% CI 0.25-0.75, p = 0.002) and mortality by 62% (OS HR = 0.38, 95% CI 0.21-0.68, p < 0.001); UFT improved DFS and OS in low-risk pMMR stage IIA colon cancer, suggesting surveillance alone may undertreat some patients. Prospective trials are warranted."

Journal • Mismatch repair • pMMR • Colon Cancer • Colorectal Cancer • Oncology • Solid Tumor

A pilot study of tegafur-uracil maintenance on survival in patients with esophageal squamous cell carcinoma following definitive chemoradiotherapy. (PubMed, Sci Rep) - "Multivariate analysis identified UFUR maintenance as an independent predictor of survival, alongside tumor stage and response to dCCRT. UFUR maintenance significantly improves outcomes in patients with ESCC following dCCRT, which might be considered as part of personalized treatment strategies to optimize prognosis in ESCC."

Journal • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma

A Case of Urinary Retention Presenting as Oxaliplatin-Induced Acute Peripheral Neuropathy (PubMed, Gan To Kagaku Ryoho) - "The patient postoperatively received FOLFOX4+bevacizumab(BEV), followed by tegafur/uracil. Increased lymph node metastasis was observed 2 years prior, and treatment with tegafur/gimeracil/oteracil was initiated...The absence of urinary retention during the postoperative administration of FOLFOX4+BEV and its onset during the current administration of CAPOX+BEV may have been due to benign prostatic hyperplasia, which developed 5 years prior. Benign prostatic hyperplasia may be a risk factor for urinary retention in patients with acute peripheral neuropathy caused by L-OHP."

Journal • Benign Prostatic Hyperplasia • Colon Cancer • Colorectal Cancer • Oncology • Pain • Solid Tumor

Osimertinib-induced aplastic anemia after curative surgery for EGFR-mutant lung adenocarcinoma. (PubMed, Respir Med Case Rep) - "The patient had previously received adjuvant oral tegafur-uracil for 2 years without any hematologic toxicity...Treatment with cyclosporine led to gradual hematologic improvement and transfusion independence. This is a rare case of osimertinib-induced aplastic anemia occurring after curative-intent surgery for NSCLC, in contrast to previously published reports that mainly involved patients with advanced or metastatic disease. Clinicians should be aware of this rare but life-threatening complication and closely monitor peripheral blood counts during treatment, particularly within the first 2-8 months after treatment initiation."

Journal • Anemia • Aplastic Anemia • Hematological Disorders • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thrombocytopenia • EGFR

Efficacy of Tegafur-Uracil Maintenance Therapy in Non-Metastatic Head and Neck Squamous Cell Carcinoma: A Meta-Analysis With Trial Sequential Analysis. (PubMed, World J Oncol) - "However, these observations currently indicate only a possible trend and should not be regarded as definitive conclusions. Further prospective randomized controlled trials are required to validate the efficacy of UFT maintenance therapy and to establish standardized protocols for patient selection and dosing."

Journal • Retrospective data • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Innovative Treatment Modalities for Laryngeal and Hypopharyngeal Cancers (AAO-HNSF 2025) - "We will present a modified NACT protocol using split-dose docetaxel and cisplatin with oral tegafur/uracil (DCU), which effectively downstages advanced tumors and supports organ preservation...Includes surgical video presentations for surgical techniques.BACKGROUND STATEMENT: Patients with laryngeal and hypopharyngeal cancers require more treatment options that prioritize organ and function preservation while minimizing complications. This topic aims to inform the audience about various treatment strategies that can enhance their patients' quality of life.Comprehensive Otolaryngology Track Statement :"

Glottic Cancer • Head and Neck Cancer • Hypopharyngeal Cancer • Laryngeal Cancer • Oncology • Otorhinolaryngology • Solid Tumor

A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA (clinicaltrials.gov) - P3 | N=10 | Terminated | Sponsor: National Health Research Institutes, Taiwan | N=147 ➔ 10 | Enrolling by invitation ➔ Terminated; Recruiting progress behind expectation

Enrollment change • Trial termination • Head and Neck Cancer • Nasopharyngeal Carcinoma • Oncology • Solid Tumor